A study reported that protective variants of APOE against risk of AD also slow cognitive decline in patients with dementia, regardless of cholesterol variations, while therapy with lipophilic statins might benefit carriers of specific genetic variants (de Oliveira et al., 2020). The gene discussed is APOE; the disease is Alzheimer disease.